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SUMMARY 
Objective: To investigate possible correlations of clinical attachment level and pocket depth with number of medi-
cations in elderly individuals.  
Methods: Intra-oral examinations for 139 patients visiting Tufts dental clinic were done. Periodontal assessments 
were performed with a manual UNC-15 periodontal probe to measure probing depth (PD) and clinical attachment 
level (CAL) at 6 sites. Complete lists of patients’ medications were obtained during the examinations. Statistical 
analysis involved Kruskal-Wallis, chi square and multivariate logistic regression analyses.  
Results: Age and health status attained statistical significance (p< 0.05), in contingency table analysis with number 
of medications. Number of medications had an effect on CAL: increased attachment loss was observed when 4 or 
more medications were being taken by the patient. Number of medications did not have any effect on periodontal 
PD. In multivariate logistic regression analysis, 6 or more medications had a higher risk of attachment loss (>3mm) 
when compared to the no-medication group, in crude OR (1.20, 95% CI:0.22-6.64), and age adjusted (OR=1.16, 
95% CI:0.21-6.45), but not with the multivariate model (OR=0.71, 95% CI:0.11-4.39). 
 Conclusion: CAL seems to be more sensitive to the number of medications taken, when compared to PD. However, 
it is not possible to discriminate at exactly what number of drug combinations the breakdown in CAL will happen. 
We need to do further analysis, including more subjects, to understand the possible synergistic mechanisms for dif-
ferent drug and periodontal responses. 
 
Keywords:  periodontal disease, medications, elderly, clinical attachment level, probing depth 
 
INTRODUCTION 
During a human life span, the body will be affected by 
different kinds of diseases, and with the expanded un-
derstanding of disease mechanisms and progression 
there has been a subsequent expansion in drug treat-
ment. Some of the drugs used will have a direct or indi-
rect impact on the gingiva and periodontal tissue.  In the 
mouth, response to bacterial plaque and activation of the 
host response is an important defense against microbial 
pathogens, but this response can be influenced by the 
medications an individual is taking.1 
 
Many studies have investigated the effects of systemic 
drugs like immunosuppressants2 corticosteroids, non-
steroidal antiinflammatory drugs (NSAIDs),3 sex hor-
mones4 and many others5-7 on periodontal health.   
 
Some of these drugs were found to have effects on the 
periodontal tissue, effects that could decrease 8 or in-
crease 9,10 the cellular response of gingival and perio-
dontal tissue to periodontal disease.  
 
Some studies reported that genetic factors were signifi-
cant in inducing gingival inflammation in association 
with the use of phenytoin, cyclosporin, and calcium 
channel blockers.11 A systematic review reported on 
phenytoin and other medications used for epileptic pa-
tients, finding associations between phenytoin and gin-
gival hyperplasia (from 16% to 94% of cases), and be-
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Cyclosporin was tested in animal models to evaluate 
effects of the drug on periodontal structures; here, histo-
logical measurements revealed that soft tissue enlarge-
ment and bone desorption were found in rats exposed to 
cyclosporine.13 In a 2013 study, Nassar et al.  Induced 
periodontitis in 3 groups of rats’ teeth, finding that a 
combination of cyclosporine and periodontitis resulted 
in the most breakdown in the bone height among all 3 
groups, and they concluded that cyclosporine interferes 
and intensifies the imbalance of alveolar bone ridge 
remodeling in rats.14 
 
Following analyses in vitro, other animal studies have 
reported that corticosteroids induced bone resorption.15 
A human cross-sectional study evaluating the long-term 
effects of inhaled corticosteroids reported that cortico-
steroids might reduce bone remodeling, causing a de-
crease in bone mineral density.16 
 
Another side effect associated with taking multiple 
drugs is xerostomia, which is associated with inflamma-
tion and bleeding from periodontal structures. In a ran-
domized controlled trial, Peker et al (2009) compared 
healthy patients not taking medication with patients 
taking medications, and found that the population on 
medications had statistically significant bleeding and 
dryness, which Paker et al. associated with the increased 
amount of missing teeth when compared to the popula-
tion not taking medications. 17,18 
 
On the other hand there are drugs that have a favorable 
biological effect on bone height, such as antibiotics.19 
Hirsch et al. (2010) presented case reports showing that 
azithromycin had favorable results in controlling in-
flammation and regeneration of the alveolar bone.20 
Metformin is another drug  associated with PD reduc-
tion and CAL gain when it was used in addition to scal-
ing and root planning. 21 
 
Thus, previous research indicates that medications have 
different effects when they are used individually.  How-
ever,  it remains unclear what effects multiple medica-
tions, taken together, have on periodontal conditions in 
the human population, although a few studies have re-
ported on relationships between the number of medica-
tions taken and periodontal effects in subjects receiving 
multiple drug therapy. In India, for example, it was re-
ported that a combination of 2 drugs (neuroleptic + anti-
cholinergic) had the highest association with clinical 
attachment loss, but increasing numbers of medications 
were not associated with increased clinical attachment 
loss. On the other hand, they reported that periodontal 
probing depth for males increased with the amount of 
medications taken. 22  
 
The aim of the current study is to assess for correlations 
of clinical attachment level and pocket depth with num-
ber of medications in an elderly population. 
 
METHODS 
This study recruited volunteers, but the population was 
not satisfactory. So in order increase minority participa-
tion, we recruited additional subjects from the Tufts 
Geriatric Outreach program (57% of participants). The 
Tufts Geriatric Outreach program, conducted at 30 loca-
tions in the greater Boston area, includes dental screen-
ing, nutritional screening, and educational sessions for 
elderly people..  
 
Inclusion criteria for enrollment in our study included: 
being a resident in a community dwelling, retaining six 
or more teeth, being diagnosed free from terminal ill-
ness or endocrine disease affecting nutrition, without 
recent rapid weight loss, and without active alcoholism. 
Patients had to be willing and able to complete a 3-
dimensional food diary in a predetermined manner.  
 
Each participant signed a consent form, agreeing to par-
ticipate in the study. The study was approved by the 
Human Investigation Review Committee of Tufts Uni-
versity. 
 
Clinical evaluations were conducted in at Tufts Univer-
sity School of Dental Medicine by an examiner, using 
artificial light, explorer, mirror, and air syringe. The 
teeth were free from stains and debris, to allow for bet-
ter diagnosis.  
 
The coronal and root caries and periodontal measure-
ments were made on all subjects according to the diag-
nostic criteria used in the US adult survey. Third molars 
were excluded from examination. Training and calibra-
tion sessions to standardize caries and periodontal 
measurements were held semi-annually. Questionnaires 
on health knowledge, attitudes and behavior, and gen-




We expected to have 80% power based on: OR of 2.33 
for the no-medication group compared with the medica-
tions group, a sample size of 67, and α=0.05. We ex-
pected about 50% drop out due to age of the participant. 
So, the total sample size was 201. The sample size was 
calculated using G*power software, version 3.1 ( Uni-
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Statistical analysis 
Descriptive statistics were expressed as mean ± SD or N 
(%). The values of each variable were compared among 
groups, according to the number of medications. The 
Shapiro-Wilk test was used to evaluate normality. Krus-
kal Wallis, chi square and Fisher exact tests were ap-
plied.  
 
The odds ratios of increasing number of medication (the 
main exposure) were used only in the first model. When 
adjusting for significant variables in other models, the 
comparison of high clinical attachment level (≥3 mm) to 
low (<3 mm), was estimated using logistic regression. 




We compared demographics and different numbers of 
medications (Table 1). The demographics of the study 
population indicated that the mean age for all groups 
was about 64 years, females, and most of the sample 
was white, married, and had completed at least 12 years 
of education. Our subjects had deep clinical attachment 
level (≥3 mm) and shallow pocket depth (< 3 mm). Age 
and disease attained statistical significance (p < 0.05) in 
One Way ANOVA and contingency table analysis (chi-
square for independence). Figure 1 shows that we found 
number of medications to have more effect on clinical 
attachment level than on pocket depth. We found the 
same results when we stratified our results by chronic 
diseases such as cardiovascular disease (CVD), diabetes 
mellitus (DM), and medically stable (having other dis-
eases or healthy) (Figure 2). 
 
Types of medications   
Cardiovascular medications were the most frequently 
used medication among this study population (Table 2). 
Diuretics were the second most frequently used, fol-
lowed by analgesic and antipsychotic drugs.   
 
Clinical attachment level and number of medications  
In a logistic regression model with clinical attachment 
level (≥ 3mm vs. <3 mm) as the outcome variable with 
number of medications as the main exposure in all mod-
els, age only or age with disease status as covariates in 
the second and third models (Table 3), we found that in 
the first model clinical attachment levels were more 
protected between 1 and 4 or 5 medications (all OR < 
1.00).  In other words, taking the required medications 
will protect the participants from recession to certain 
extent.  However, patients taking 6 or more medications 
were 1.20 times more likely to have increased recession 
(OR 1.20, 95% CI 0.22–6.64).  
 
We found the same pattern after adjusting for age.  But 
when we adjusted for both age and disease status, the 
pattern disappeared:  taking any number of medications 
was protective against recession. 
 
Table 2 Common medications used among study sam-
ple 
Class Frequency 
Cardiovascular Agent 46 
Diuretics 32 
Analgesic  18 




Respiratory Drugs 4 
Adrenal Glucocorticoid 4 
Antidiabetic 4 
Thyroid Supplement 4 
Female Reproductive Agent  3 




Anticoagulant  2 
Vitamin Supplement  2 
Gastric Drugs 2 
CNS Agent 1 
Antirheumatic, Cytotoxic 1 
Anti diarrheal 1 




The population sample size investigated in this report 
was 139.  Almost half of this population was not taking 
medication (N=71), while the other half took 1 or more 
medications (N=68). Most population individuals were 
white Caucasians who are married. Other variables, 
such as CAL, PD, years of smoking, health condition, 
and years of education, were similar among all the 
groups. 
  
The relative frequencies of the use of certain medication 
classes – cardiovascular drugs followed by diuretics, 
followed by analgesics and anti-psychotics  – is not sur-
prising, given the relative frequency of heart and arterial 
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Table 1 Descriptive statistics of the study sample 








4 or 5 
 N=8 
6 or more 
N=6 
P value 
Age (mean ±SD)  63.68±10.62 69.0±5.68 60.52±12.55 62.67±11.88 66.63±9.94 67.86±12.42 <0.001* 
Gender, n(%)       0.889 
 Male 37(52.11) 7(41.18) 11(47.83) 4(36.36) 3(37.50) 3(50.0)  
 Female 34(47.89) 10(58.82) 12(52.17) 7(63.64) 5(62.50) 3(50.0)  
Race, n(%)       0.436 
 White 65(92.86) 16(94.12) 23(92.0) 11(91.67) 7(87.50) 4(66.67)  
 African American 5(7.14) 1(5.88) 2 (8.0) 1(8.33) 1(12.50) 2(33.33)  
Marital status, n(%)       0.415 
 Single 9(12.86) 5(29.41) 2(8.7) 3(27.27) 1(12.50) 1(16.67)  
 Married 40(57.14) 7(41.18) 17(73.91) 7(63.64) 4(50.0) 3(50.0)  
 Others 21(30.0) 5(29.41) 4(17.39) 1(9.09) 3(37.50) 2(33.33)  
Clinical attachment level (CAL) (mean ±SD) 3.55±1.08 3.24±0.95 3.11±0.73 3.51±1.37 3.11±0.49 4.08±0.49 0.220 
Clinical attachment level (CAL) n(%)       0.387 
 ≥ 3 mm  23(32.39) 9(52.94) 13(52.0) 5(41.67) 4(50.0) 1(16.67)  
 < 3 mm 48(67.61) 8(47.06) 12(48.0) 7(58.33) 4(50.0) 5(83.33)  
Pocket depth (mean ±SD) 2.03±0.54 2.06±0.53 2.01±0.38 2.11±0.64 2.08±0.38 2.08±0.38 0.095 
Pocket depth (n,%)       0.921 
 ≥ 3 mm  66(92.96) 16(94.12) 24(96.0) 11(91.67) 8(100.0) 6(100.0)  
 < 3 mm 5(7.04) 1(5.88) 1(4.0) 1(8.33) 0(0.0) 0(0.0)  
Year of smoking (mean±SD) 13.63±17.37 9.35±14.12 16.60±13.72 16.67±15.98 6.00±9.30 12.00±17.32 0.388 
Number of cigarettes per day 7.52±9.61 6.00±11.48 16.36±16.97 9.83±9.20 5.00±9.26 7.71±14.72 0.052 













Disease (n,%)       0.030* 
 CVD 12(16.90) 8(47.06) 9(36.0) 2(16.67) 3(37.5) 4(66.67)  
 Diabetes 16(22.54) 4(23.53) 2(8.0) 3(25.00) 1(12.5) 1(16.67)  
 Medically stable 43(60.56) 5(29.41) 14(56.0) 7(58.33) 4(50.0) 1(16.67)  
Year of education (mean±SD) 13.30±2.163 12.59±2.79 13.30±2.40 13.90±2.69 13.63±3.02 12.17±4.67 0.884 
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Table 3 Association between number of medications and clinical attachment level among study sample 
 OR (95% CI) P-value for χ2* OR (95% CI) P-value for χ2* OR (95% CI) P-value for χ2* 
Number of medication  0.364  0.354  0.220 
           No medication 1  1  1  
            1 0.43(0.15-1.25)  0.41(0.14-1.21)  0.31(0.10-0.98) §  
            2 0.44(0.18-1.12)  0.45(0.18-1.16)  0.35(0.13-0.93) §  
            3 0.67(0.19-2.34)  0.68(0.19-2.36)  0.67(0.19-2.39)  
            4 or 5 0.48(0.11-2.09)  0.47(0.11-2.04)  0.37(0.08-1.73)  
            6 or more 1.20(0.22-6.64)  1.16(0.21-6.45)  0.71(0.11-4.39)  
Age  -  1.01(0.98-1.04) 0.602 1.00(0.97-1.04) 0.880 
Disease       
 CVD -  -  1  
 Diabetes -  -  0.30(0.10-0.92) §  
 Medically stable -  -  0.39(0.15-1.03)  
OR, odds ratio; CI, confidence interval. 
* p value for trend χ2 test. 
§ p value < 0.05 
 
 
Figure 1 Effect of number of medications on CAL and PD  
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The logistic regression analysis used in this study 
showed that when the number of medications was 
between 1 and 5 there was a greater likelihood of 
preventing  CAL loss.  With <3 mm CAL considered 
healthy or having no previous bone loss, and >3mm 
considered diseased or having previous bone loss, a 
change from CAL maintenance to CAL loss was seen in 
patients taking more than 5 medications; for those 
patients, there was 1.2 times the chance to develop CAL 
loss.   
 
On the other hand, periodontal probing depth did not 
change for any amount of medications taken. This is 
potentially an important finding, given that between 
1998 and 2008 the percentage of patients taking 
medication who were taking 5 or more drugs increased 
from 6% to 11% in the United States. 27  
 
In our second model, introducing age as a variable in 
analysis, the odds ratio for CAL loss (>3 mm) is 1.16 
for patients taking more than 5 medications.  Thus, age 
had no impact in these subjects. When the disease status 
was included into the model along with the age, none of 
the medications amount groups had CAL loss.  Our 
results seem to support Ciancio et al’s findings (1997, 
2005) that while most medications increased the risk of 
developing caries and periodontal disease, a few 
medications might decrease the risk of periodontal 
breakdown.28,29 
 
Though our study findings are significant, our research 
had limitations in terms of sample size and population 
homogeneity, and further research in multicenter set-
tings is needed to study the relationship between num-
ber of medications and CAL.   
 
Conclusion 
This study has demonstrated that multiple-medication 
regimens in elderly patients are more likely to affect 
clinical attachment level than pocket depth. It is, how-
ever, not possible to discriminate exactly at what drug 
combination threshold the breakdown in clinical at-
tachment level occurs – this seems dependent upon drug 
type - but it is likely that intake of 5 or more medica-
tions should raise concerns about  attachment level. A 
larger study is needed to investigate this issue further.   
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